Back to results
US 2026/0294883 A1Published application
Pharmaceutical composition for the treatment of post-traumatic stress syndrome
AssigneeKinnov Therapeutics
InventorsFabrice TROVERO, Philippe BERNARD, Jean-Pol TASSIN
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition in the treatment of the post-traumatic stress syndrome in humans includes: a compound having an antagonist action on serotonergic 5-HT2 receptors selected as cyproheptadine; and a compound having an antagonistic action on alpha1-noradrenergic receptors chosen among prazosin, alfuzosin, terazosin, tamsulosin, silodosin and doxazosin.
Claims7
A pharmaceutical composition for use in the treatment of the post-traumatic stress syndrome in humans comprising:
- a compound having an antagonist action on serotonergic 5-HT2 receptors chosen as being cyproheptadine;
- and
- a compound having an antagonistic action on alpha1-noradrenergic receptors chosen among prazosin, alfuzosin, terazosin, tamsulosin, silodosin and doxazosin.
A pharmaceutical product for use in the treatment of the post-traumatic stress syndrome in humans containing:
- a compound having an antagonist action on serotonergic 5-HT2 receptors chosen as being cyproheptadine;
- and
- a compound having an antagonist action on alpha1-noradrenergic receptors chosen among prazosin, alfuzosin, terazosin, tamsulosin, silodosin and doxazosin;
- as a combination product for simultaneous, separate or spread out administration.
1 more element
Dependencies are inferred from the claim text.